XXXXXXXX KOMISE X XXXXXXXXX XXXXXXXXX (XX) č. 1062/2014
xx xxx 4. xxxxx 2014,
týkající xx xxxxxxxxxx programu xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx, xxxxx xxxx uvedeny v xxxxxxxx Evropského parlamentu x Xxxx (EU) č. 528/2012
(Xxxx x xxxxxxxx xxx XXX)
XXXXXXXX XXXXXX,
s ohledem xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,
x xxxxxxx xx xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. května 2012 x xxxxxxxx xxxxxxxxxx přípravků na xxx x jejich xxxxxxxxx (1), x xxxxxxx xx xx. 89 xxxx. 1 xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx,
xxxxxxxx x xxxxx xxxxxxx:
(1) |
Xxxxxxxx Xxxxxx (XX) x. 1451/2007 (2) xxxxxxx prováděcí xxxxxxxx xxx program xxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxx xxxxx (dále xxx „xxxxxxx přezkumu“), xxxxx xxx xxxxxxx v souladu x xx. 16 odst. 2 směrnice Xxxxxxxxxx xxxxxxxxxx a Rady 98/8/XX (3). Xxxxxxx xxxx xxxxxxxx xxxx zrušena x xxxxxxxxx xxxxxxxxx (XX) x. 528/2012, xxxx xx xxx prováděcí xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx nařízení. |
(2) |
Xx xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxx a xxxx xxxxxxxxx, které xxxxx xxx xxxxxxxx na trh x xxxxxxxxx xxxxx přechodných xxxxxxxxxx xxxxxx 89 xxxxxxxx (XX) č. 528/2012 x xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx. Xxxx xx xxxx xxx x x xxxxxxx xxxxxxxxx účinné látky x xxxx přípravku, xxxxx jsou xxxxxxxxx x programu přezkumu. |
(3) |
Xxxxx xxxxxxxxx využíval xxxxxxxx xxx xxxxxxxxx a krmiva xxxxx článku 6 xxxxxxxx (ES) x. 1451/2007, xxx nevztahuje se xx něj xxxxxxx xxx potraviny x xxxxxx xxxxxxx x xx. 2 odst. 5 xxxx. x) xxxxxxxx (EU) x. 528/2012, měly xx xxx xxxxxx xxxxx, xxxxx xxxxxxxx, xxxxxxxxx x xxxxxxxx xxxxxxxx xxx xxxxxxxxx typ xxxxxxxxx. X xxxxxxxx xxxxxxxxxxxxxx předpisů xx xxxx xxx xxxxxx xxxxxxxx xx xxx x xxxxxxxxx umožněno xx xx xxxxxxxx uvedeného hodnocení. Xxxxxx xxxxxxxxxxx xxxxxxxxxx xx xxx vymezit, xxxxx xxxxxxxxx xxxxxx xxxxxxxxxx využijí. Totéž xx xxxx platit x xxxxxxxxx, kdy neoznámení xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxx xxxxxxxx xxxx přípravků v nařízení (XX) x. 528/2012 oproti xxxxxxxx xxxxxxx xx xxxxxxxx 98/8/XX nebo xx řádně odůvodněno xxxxxxxxxxx Xxxxxx přijatým x xxxxxxx x xx. 3 odst. 3 xxxxxxxx (XX) x. 528/2012, xxxxxxxxxxx (xxxxxxxxx xxxxxxxxxxx xx xxxx C-420/10 (4)) xxxx xxxxxxxxx xxxxxx Xxxxxx či příslušných xxxxxx xxxxxxxxx xxxxx, xxxxx se xxxxxxxx xxxxxxx. |
(4) |
Xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx, xxxxx již není xxxxxxxx do programu xxxxxxxx, x této xxxxx sestává xxxx xx x ní xxxxxx, avšak xxxxxxxx xx používání xxxxxx xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxx xxxxxxxx, xxxx xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x xxxxxxxx xx xxx xxxxxxxx na xxxx xxxxxxxxxxxx, xx xxxxxxxx xxxxxxxx a po xxxxxxxx xxxx. |
(5) |
X zájmu jednotnosti x xxxxxxxxxxxx xx měl xxx xxxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxx xxxxxxx x postupem stanoveným xxx žádosti xxxxxxxxxx xxxxx článku 7 xxxxxxxx (XX) x. 528/2012 xxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (EU) č. 88/2014 (5). |
(6) |
Xxx xxxxx, xxxxx xxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxxx pro xxxxxxx, xx měl hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx návrh harmonizované xxxxxxxxxxx x xxxxxxxx xxxxx xxxxx čl. 37 xxxx. 1 xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 (6), xxxxx xxx x xxxxxxxxx vlastnosti xxxxxxxxxx xxxxx, x xxxxxxx xx xxxx xxx xxxxxxxxx xxxxx xxxxxxxxx státu xxxxxxxxx xxxxx týkající xx jiných xxxx xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx příslušný xxxxx xx měl xxxx xxxxxxxxxxx agenturu v xxxxxxx xxxxx, které xx xxxxxxxxx xxxxxxxx xxx xxxxx xxxxxxxxxxxx, xxxxxxxxxxxxxxx xx xxxxxxx, nebo xxxxx, xxxxx xx xxxxx být považovány xx látky x xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx. |
(7) |
Xxx bylo zajištěno, xx xxxxxxx přezkumu xxxx dokončen do xxxxxxxx data uvedeného x xx. 89 xxxx. 1 nařízení (XX) x. 528/2012, mělo xx xx xxxxxxxxx xxxxxx xx kombinace xxxxxx xxxxx a typu xxxxxxxxx, x nichž xxxx příslušné xxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx x xxxxxxxx (ES) x. 1451/2007 xxxx v tomto xxxxxxxx. Xxxxx xxxx by xx xxxx xxxxxxxx xxxxxx xxxxx pro xxxxxxxxx hodnocení, přičemž xx xx xxxx xxxx x xxxxx xxxxxxx, xx xxxxxxx xx xxxxx xxx xxxxxxxxx xxxx xxx xxx před uplynutím xxxxxx xxxx. |
(8) |
Xxxxxxx xxxxxxxx xx xxxxxxx I xxxxxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxxx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx xx xxxxx. Xx proto xxxxxx x xxxx xxxx xxxxxx xxxxxxx x xxxxxxxx xx uvedené přílohy xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6. |
(9) |
Xxx xxxxxx na čl. 90 odst. 2 xxxxxxxx (XX) x. 528/2012 xxxxxxx z článku 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx xxxxxxx x xxxxxx 10 xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx xxxxxxxx povolování xxxxxxxxxx xxxxxxxxx ve všech xxxxxxxxx. Xx xxxxx xxxxxx xxxxx xxxxx xxxxxxxxx xxxx kritéria xx xxxxx hodnoceních xxxxxxxx xxxxx. |
(10) |
Xxxxxxxxxxx účastník programu xxxxxxxx xx xxx xxx xxxxxxx xx xx xxxxxxxx xxxxxx xxxxxxxx xx xxxxxxxxxxx xxxxxxxxxxx xxxx xxx xxxxxxxx za předpokladu, xx xxxxx xxxx xxxxxxx xx zpoždění xxxxxxxxx z důvodu xxxxxxxxx xxxxxxxx x údajům, xxxxxxx xxxxx by xxxxxxxxxxx účastník xxxxx xxxxxxxxx xxxxx xxxxx. |
(11) |
Protože xx účast v programu xxxxxxxx dobrovolná, xxxx xx xxx xxxxxxxxxx xxxxxxxx od xx xxxxxxxxx. Xxxxx x xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx možnost převzít xxxxxxx, xxxxxx-xx xxxx xxxxxxxx xxxxxxx xxx xxxxxx, xxxxx xxx xxxxxxx ke xxxxxxxx xxxxxxxx přezkumu, x xxxxxxxx-xx agentura xxx xxxxxxxx xx svém xxxxxxxxxx. |
(12) |
Xxxxx xx xxx xxxxxxxxx xxxxxx látky xxxxx, xx xxxxxxxx xxxxxxxxx xxxxxxxx do programu přezkumu xxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx hodnocené xxxxx, x x hodnocení xxxxx xxxxxxx xxxxxx ohledně xxxxxxxx xxxxxxxxx xxxxxxxx xxxxx, mělo xx xxx xxxxx xxxx xxxxx x xxxxxxx xxxxxxxxx xxxxx definovat x xxxxxxx xxxxx osobám, aby xxxxxxxx podporu této xxxxxxxxx xxxxxxxx látky. |
(13) |
Xxxxxxx xxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxxx x době xxxxxxx xxxxxx nařízení xxxxxxxxxxx xxxxxx účastníkem. Xxxxx xx týká určitých xxxxxxxxxxxxx, xxxxxx xxxxx xx. 4 xxxx. 4 nařízení (XX) č. 528/2012 tyto xxxxxxxxx xxxxx xxxxxxxx, xxxxx tak xxxx xxxxxxxx stanoveno. X xxxxxxxxx látek x xxxxxxxxxxxxx xx měly xxx xxxxx možnost xxxxxxx účast, protože xxxxx by tyto xxxxx x xxxxxxxxxxxxx xxxxxx xxx z xxxxxxxx xxxxxxxx vyloučeny. |
(14) |
Xxx bylo xxxxxxxxx, xx xxxxx xxxxx nezůstane x xxxxxxxx xxxxxxxxxxx xxx xx xxx nebude xxxxxxxx, xxxx xx xxxxxxxx byla vyhodnocena, xxxx xx xxxxxxxx xxxxx, xxxxx xxxxx xxxxxx xxxxxxxxx, v xxxxxxxx nebo xxxx xxxxxxxx podléhat xxxxxxxxxx xxxxxxxxxx xxxxx x xx, |
XXXXXXX XXXX NAŘÍZENÍ:
XXXXXXXX 1
XXXXXXX A XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx pravidla xxx xxxxxxxxx pracovního xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx všech xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx x&xxxx;xxxxxx&xxxx;89 nařízení (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Xxx xxxxx xxxxxx xxxxxxxx se xxxxxxx tyto xxxxxxxx:
x) |
„rozhodnutím x xxxxxxxxxxx“ xx xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx podle xx. 9 xxxx. 1 písm. b) nařízení (XX) x. 528/2012 nebo xx. 89 xxxx. 1 třetího xxxxxxxxxxx xxxxxxxxx nařízení, xxxx xxxxxxxxx xxxxxxxxx xx xxxxxxx X xxxx XX xxxxxxxx 98/8/ES; |
x) |
„kombinací látky x xxxx přípravku zařazenou xx xxxxxxxx xxxxxxxx“ xx xxxxxx kombinace látky x xxxx xxxxxxxxx xxxxxxx x xxxxxxx II, xxxxx xxxxxxx tyto xxxxxxxx:
|
c) |
„účastníkem“ xx xxxxxx osoba, která xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx nebo xxxxxxxxxx xxxxxxxx, které odpovídá xxxxxxxxxx podle xx. 17 xxxx. 5 xxxxxx xxxxxxxx, xxxx xxxxxx jménem xxxx xxxx žádost xxxx xxxxxxxx xxxxxxxxxx; |
x) |
„xxxxxxxxxx xxxxxxxxxx orgánem“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx státu xxxxxxxxx x příloze XX xxxxxx xxxxxxxx, xxxxxx x xxxxxxx x xxxxxxx 81 nařízení (XX) x. 528/2012. |
XXXXXXXX 2
POSTUP HODNOCENÍ XXXXXXXXXXX
Xxxxxx 3
Žádost x xxxxxxxxx nebo xxxxxxxx xx xxxxxxx X xxxxxxxx (EU) x. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx či xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012 xxxx xxxxx pouze xxxxxxxx, x xxxxx xxxxxxxx xxxxx agentura x xxxxxx, že xxxxxxxx xxxxxxxxxx xxxxx čl. 17 xxxx.&xxxx;5 tohoto xxxxxxxx.
Xxxxx xx žádost týká xxxxxxxx do přílohy X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012, xxxx xx xxxxx xxxxx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 uvedené xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxxxxx x&xxxx;xxxxxxxx 1 xx podávají xxxxxxxx xx&xxxx;xxxx xxx xx prohlášení x&xxxx;xxxxxxx x xxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Přijetí xxxxxxx
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 564/2013 (7) x xxxxxxx žádost, xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx 30 xxx. O xxxx skutečnosti informuje xxxxxxxxx i xxxxxxxxx xxxxxxxxx orgán.
2. Po xxxxxxxx xxxxxxxx splatných xxxxx xxxxxxxxxxx nařízení (XX) x. 564/2013 xxxxxx xxxxxxxx žádost x xxxxxxxxx x xxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx orgán, xxxxxxx xxxxx datum xxxxxxx xxxxxxx x xxxx xxxxxxxxx xxxxxxxxxxxxx xxx.
3. Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxx 1 tohoto xxxxxx lze podat xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 77 xxxxxxxx (XX) x. 528/2012.
4. Xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx x poplatku xxxxxxxx xxxxx xx. 80 xxxx. 2 xxxxxxxx (XX) x. 528/2012 xx 30 xxx xxxx, xx xxxxxxxx xxxxxxx žádost, x xxxxxxx xxxxxx, pokud xxxxxxxx xxxxxxxxx poplatek xx lhůtě 30 xxx. X této xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x agenturu.
Xxxxxx 5
Potvrzení xxxxxxx x xxxxxxxxx xxxx xxxxxxxx xx kategorie 6 xxxxxxx X xxxxxxxx (XX) x. 528/2012
1. Xxxxx xxxxxxxx xxxxxx xxxxx xx. 4 xxxx. 2 xxxxxx x xxxxxxxxx xxxx zařazení xx xxxxxxxxx 6 přílohy X xxxxxxxx (XX) č. 528/2012, xxxxx xxxxxxxx xxxxx xxxxxxxxxx v souladu x xx. 6 xxxx. 1 a 2 xxxxxxxxx xxxxxxxx, x xxx xxxxxxxx xxxxxxxx xxxxx xx. 4 odst. 4, xxxxxxxxx xxxxxxxxx orgán xxxxxx xxxxxxx do 30 xxx xx zaplacení poplatků.
2. Pokud xxxxxxxxx příslušný orgán xxxxxxx xx xxxxxxxxx dokumentaci xxxxx nařízení (XX) x. 1451/2007, avšak ta xxxxx xxxxxx xxxxxx xxxx xxxxx xxxxx xxxxxx 13 uvedeného xxxxxxxx, potvrdí xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X případech xxxxxxxxx x odstavcích 1 x 2 xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx xxxxxxxxx xxxxxxx ani xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxx.
4. Pokud hodnotící xxxxxxxxx xxxxx xxxxxx, xx xxxxxx je xxxxxxx, xxxxx účastníkovi, xxxx doplňující informace xxxx k xxxxxxxxx xxxxxxx xxxxx, x x xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxx. Xxxx xxxxx xxxxx xxxxxxxxxx 90 xxx.
Xxxxxxxx-xx xxxxxxxxx xxxxxxxxx xxxxx, xx předložené doplňující xxxxxxxxx postačují xx xxxxxxx xxxxxxxxx xxxxxxxxx x odstavci 2, xxxxxxx xxxxxx xx 30 xxx xx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx.
Jestliže xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, hodnotící xxxxxxxxx xxxxx xxxxxx zamítne x xxxxxxxxx x xxxx skutečnosti xxxxxxxxx x xxxxxxxx. X xxxxxx xxxxxxxxx xx xxxxx xxxxxxxx zaplacené x xxxxxxx x xx. 80 xxxx. 1 x 2 xxxxxxxx (EU) x. 528/2012.
Xxx potvrzení žádosti xxxxxxxxx xxxxxxxxx orgán xxxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxxxxx x xxxxx xxxxxxxxx xxxxxx x xxxxx xxxxx xxxxxx potvrzení.
Xxxxxx 6
Xxxxxxxxx xxxxxxx
1. Xxxxx xxxxxx xx xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
x) |
xx-xx xxxxxx xxxxxxxxx xxxxx xxxxxx 5; |
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxxxx xxxx xxxxxx xxxxx xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, ale xxxxx xxxxxxxxxxx Xxxxxx zprávu xxxxxxxxxxx orgánu podle xx. 14 xxxx. 4 xxxxxxxxx xxxxxxxx; |
x) |
xxxxx agentura xxxxxxx xxxxxx o xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 nebo 5 přílohy I nařízení (XX) x. 528/2012 xxxxx xx. 4 xxxx. 2 x xxx xxxxxxxx poplatek xxxxx xx. 4 xxxx. 4. |
2. Xxxxxxxxx xxxxxxxxx orgán zhodnotí xxxxxx xxxxx xxxxxx 4 x 5 xxxxxxxx (EU) x. 528/2012 a případně xxx xxxxxxx návrhy xx xxxxxx xxxxxxxxx xx xxxxx předložené x xxxxxxx x xx. 6 xxxx. 3 xxxxxxxxx xxxxxxxx x xxxxx hodnotící xxxxxx x xxxxxx xxxxx xxxxxxxxx agentuře.
3. Pokud xxxxxxx kombinaci látky x xxxx xxxxxxxxx xxxxxxxxx několik xxxxxxxxx, xxxxxxxxx xxxxxxxxx příslušný xxxxx xxxxx xxxxx xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx x xxxxxx zašle x xxxxx x xxxxxx xxxx, podle xxxx, xx nastane později:
x) |
365 xxx xx xxxxxxxxx xxxxxxxxx uvedeném v odst. 1 xxxx. x), xxxxxx xxxxxxxx xxxxxxxx v odst. 1 xxxx. x) xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx x xxxx. 1 písm. c) x xxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx; |
x) |
ve xxxxx xxxxxxxxx v příloze XXX. |
4. Xxxx tím, než xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx xxx xxxxxx xxxxxxxx, umožní xxxxxxxxxxx xxxxx xx 30 xxx k xxxxxxxxx xxxxxx x k xxxxxxx hodnocení xxxxxxx xxxxxxxxxx. Xxxxxxxxx příslušný xxxxx tyto xxxxxxxxxx xxxxxxxxxxxxx způsobem zohlední x xxxxxxxxx xxxx xxxxx hodnocení.
5. Xxxxx xx xxxxx, že xxxx x xxxxxxxxx xxxxx xxxxxxxxxx informace, xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx, xxx tyto xxxxxxxxx ve stanovené xxxxx předložil, x xxxxxxxxx o xxx xxxxxxxx.
Xxxxx 365 xxx xxxxxxx x xxxxxxxx 3 xx xxxxxxx xx xxxx xxx xxx vznesení xxxxxxxxx xx dne obdržení xxxxxxxxx. Xxxxx xx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx okolnostmi, xxxxxxxxx xxxxxxxxxx následující lhůty:
x) |
365 xxx x xxxxxxx, xx xx xxxxxxxxxx xxxxxxxxx xxxxxx otázek, xxxxx xxxxxx xxxxxx x xxxxx xxxxxxxx 98/8/XX xxxx x xxxxx xxxxxxx xxxxxxxxxxx xxx xxxxxxxxxxx xxxxxxx směrnice; |
x) |
180 dní xx xxxxx xxxxxxxxx případech. |
6. Pokud xxxxxxxxx xxxxxxxxx orgán xxxxxx, xx existují xxxxx xxxxxxx xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxxx prostředí xxxxxxxxxxx x xxxxxxxxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx přípravků xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx účinné xxxxx, xxx xxxxx xxxxxxxxxxxx x xxxxxxx s požadavky příslušných xxxxx xxxxxx XX xxxx 3 xxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) č. 1907/2006 (8) x xxxxxx xx xx xxxxx xxxxxx.
7. X xxxxxxx xxxxxxx xx dokončení hodnocení xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx bez zbytečného xxxxxxx x xxxxxxxxxx při xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxx 3:
x) |
xxxxxxxx xxxxx agentuře xxxxx xx. 37 odst. 1 xxxxxxxx (XX) x. 1272/2008, xxxxxxxx xx domnívá, xx xx xxxxxxx xxxxx z kritérií xxxxxxxxx x xx. 36 xxxx. 1 xxxxxxxxx xxxxxxxx, xxx xxxx náležitě řešeno x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
x) |
xxxxxxxxxx x xxxxxxxxx, xxxxx xx domnívá, xx xxxxx x xxxxxxxx xx. 5 xxxx. 1 písm. d) xxxx x) xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxx xx. 10 xxxx. 1 xxxx. x) xxxxxxxxx nařízení xxxx xxxxxxx, xxx nejsou xxxxxxxx xxxxxx x xxxxxxx XXX xxxxxxxx (XX) x. 1907/2006 xxxx x xxxxxxx xxxxxxxx x xx. 59 xxxx. 1 xxxxxxxxx nařízení. |
Xxxxxx 7
Xxxxxxxxxx agentury
1. Xxxxx xxxxxx xx xxxxxxx, xxxxx xxxxx xxxxxxx x xxxxxx xxxxxxxx:
a) |
xxxxx hodnotící xxxxxxxxx orgán xxxxxxxxx xxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 2 x xxxxxxxx xxxxxxxxx návrh xxxx provedl xxxxxxxxxx xxxxx xx. 6 xxxx. 7; |
x) |
xxxxx xxxx xxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 14 xxxx. 4 xxxxxxxx (XX) x. 1451/2007, xxx xxxxxxxxx zprávu xxxxx xxxxxxxxxxxx Stálý xxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xx. 15 xxxx. 4 xxxxxxxxx xxxxxxxx. |
2. Xx xxxxxxx xxxxxx xxxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx kombinace xxxxx x xxxx xxxxxxxxx xxxx xxxx xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 přílohy X xxxxxxxx (XX) x. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx hodnotícího xxxxxxxxxxx xxxxxx.
Xxxxxxxx zahájí přípravu xxxxxxxxxx x xxxxx x xxxxxx xxxx, podle xxxx, xx nastane xxxxxxx:
x) |
do xxx xxxxxx xx xxxxxxx xxxxxx; |
b) |
ve xxxxx xxxxxxxxx x xxxxxxx III. |
Xxxxxxxx xxxxxxxx stanovisko Xxxxxx xx 270 dnů xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx xx mají xxxxxxxx
1. Xxx xxxxxxxx xxxxx xxxxxxxxxx xxxxx čl. 7 xxxx. 2 agentura prověří, xxx účinná xxxxx xxxxxxx některé z kritérií xxxxxxxxx x xx. 10 odst. 1 xxxxxxxx (XX) x. 528/2012, x xxxx otázku zmíní xx xxxx xxxxxxxxxx.
2. Xxxx xxxx xxxxxxx xxxxxx 66 x 67 nařízení (EU) x. 528/2012, dříve než xxxxxxxx xxxxxxxx xxx xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx x xxxxxxx látkách, xxxxx xx xxxx xxxxxxxx, xxxxx xxxxxxxxx 60 dnů; v xxxx xxxx xxxxx xxxxxxxxxx třetí strany xxxxxxxxx příslušné xxxxxxxxx xxxxxx informací x xxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxx náležitě zohlední x xxxxxxxxx fázi xxxxxxxx xxxxx xxxxxxxxxx.
3. Xxxxx xx xxxxxx xxxxx xxxxxxxxx a splňuje xxxxx x xxxxxxxx xxxxxxxxxxx x xx. 10 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xxxx být xxxxxxxx xx xxxxx, xxxxx xx xx xxxxxxxx, v nařízení xxxxxxxx x xxxxxxx s čl. 89 xxxx. 1 xxxxxx xxxxxxxxxxxx uvedeného xxxxxxxx.
Xxxxxx 9
Xxxxxxxxxx Xxxxxx
Xx xxxxxxxx xxxxxxxxxx agentury xxxxx xx. 7 xxxx. 2 Xxxxxx xxx xxxxxxxxxx xxxxxxxx připraví návrh xxxxxxxxxx pro xxxxxxx xxxxx xx. 89 xxxx. 1, xxxx xxxxxxxx podle xx. 28 xxxx. 1 xxxxxxxx (XX) x. 528/2012.
KAPITOLA 3
XXXXX XXXXX XXXXXXXX PŘEZKUMU
Článek 10
Xxxxxxxxx xxxx nahrazení xxxxxxxxx xx xxxxxxxx dohodě
1. Roli xxxxxxxxx xx xxxxx xx xxxxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxxxxx x potenciálním xxxxxxxxxx xxxxxxx xxxx xxxxxx xx předpokladu, že xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xx xx xxxxxxx údaje xxxxxxxxxx xxxx uvedené xxxxxxxxxx účastníkem.
2. Oznámení xxx xxxxx xxxxxx článku xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx pro xxxxxxxx xxxxxxxxx xxxxxxxxx x článku 71 xxxxxxxx (XX) x. 528/2012 (xxxx xxx „xxxxxxxx“) x&xxxx;xxxxxxxx xxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxx k přístupu.
3. Po xxxxxxxx xxxxxxxx splňujícího xxxxxxxxx xxxxx xxxxxxxx 2 agentura aktualizuje xxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxx xx totožnosti xxxxxxxxx.
4.&xxxx;&xxxx;&xxxx;Xxxxx xxxxxxx na území Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx xxxx se xxxxxxxxx x xxxxxxxxxxx xxxxx xxxxxx článku, xx xxx xxxxx xxxxxx 95 nařízení (XX) x.&xxxx;528/2012 xxxxxxxxxx xx xxxxx, která xxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Xxxxxxxxxx xxxxxxxxx
1. Xx xx xx to, xx xxxxxxxx xxxxxxxxx x účasti xx xxxxxxx kombinace xxxxx x xxxx přípravku x xxxxxxxx xxxxxxxx, x xxxxxx xxxxxxxxx:
x) |
xxxxx xxxxxxxxxx agenturu xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxx záměru xxxxxxxxx; |
x) |
xxxxx xxxxxxxxxxx xxxxxx xx lhůtě uvedené x xx. 3 xxxx. 2; |
c) |
xxxxx jeho xxxxxx xxxx xxxxxxxxx xxxxx xx. 4 xxxx. 1, xx. 4 odst. 4 xxxx xx. 5 xxxx. 4; |
x) |
xxxxx nepředložil xxxxxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxx x xx. 6 xxxx. 5; |
x) |
xxxxx xxxxx nezaplatil xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxx nebo xxxxxxxx. |
2. Xxxxxxxxxx xx považuje xx xxxxxxxxx včas, pokud x xxxx xxxxxxx xx datu, xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx orgánu xxxxx xx. 6 odst. 4 tohoto xxxxxxxx.
Xxxxxx 12
Xxxxxxxx xxxxxxxx xxxxxxxxxx
1. Xxxxx je x xxxxxxx odstoupení informován xxxxxxxxx xxxxxxxxx orgán, xxx xxxxxx xxxxxxxx, xxxxxxxxx xx xxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx prostřednictvím xxxxxxxxx.
2. Xxxxx xx x xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx týkající se xxxxxxxxxx xxxxxxxxx.
3. Xxxxx x xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxx xxxx role xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxxxxxx o tom xxxxxxxx xxxxxxxxxxxxxxx rejstříku Xxxxxx.
Xxxxxx 13
Xxxx xxxxxxxx xxxxxxxxx látek
1. Xxxxx hodnocení xxxxxxxxx xxxxxx látky xxxxxxxx vyvodit xxxxxx xxxxxxxx se xxxxx, xxx xxxx xxxxxxx x xxxxxxx XX, hodnotící příslušný xxxxx xx konzultaci x dotyčným účastníkem xxxxxxx xxxxx xxxxxxxx xxxxx. Hodnotící příslušný xxxxx x xxx informuje xxxxxxxx.
2. Xxxxxxxx v rejstříku xxxxxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx.
Xxxxxx 14
Xxxxxxxx role xxxxxxxxx
1. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xxxx xxxxxxxxx xxx xxxxxxxxx látky a typu xxxxxxxxx, pokud xxxxxxx xxxxx x xxxxxx případů:
a) |
xxxxx xxxxxxx účastníci podporující xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxx xxxxxxxxxx xxxxx xxxxxx 11 x xxxxxx xxxx xxxxxxxxx xxx danou xxxxxxxxx xxxxxx předtím xxxxxxxx; |
x) |
na základě xxxx xxxxxxxx xxxxx xxxxxx 13; x xxxxx xxxxxxx xx výzva xxxx xxxxx xx látky, xx xxxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX, xxx xxxxxxx nová xxxxxxxx xxxxx. |
2. Xx xxxxxxxx xxxxxx xxx xxx xxxxxxxxxx xxxxx xxxxxxxx 1 xxxx kterákoli osoba xxxxxxxxx oznámení xxx xxxxxxxxx podle článku 17.
3. Xx xxxxxxxx měsíců xx xxxx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx může xxxxxxxxx xxxxx oznámit kombinaci xxxxx x xxxx xxxxxxxxx xxxxxxxxx do části 2 xxxxxxx XX podle xxxxxx 17.
Xxxxxx 15
Kombinace xxxxx x typu xxxxxxxxx xxxxxxxxx xxx zařazení xx programu xxxxxxxx
Pokud xxxxxxxx přípravek, xxxxx xxxxx xx oblasti xxxxxxxxxx xxxxxxxx (EU) x. 528/2012 x xx xxxxxx xx trh, xxxxxxx xx stávající xxxxxx xxxxx, xxx xxxx xxxxxxxxx ani xxxxxxxx do xxxxxxxx xxxxxxxx xxx xxxxx xxx přípravku a xxxx xxxxxxxx xx xxxxxxx X xxxxxxxxx xxxxxxxx, tuto xxxxx xxxxxxxx nebo xx x ní vyrábí, xx xxxxxxx xxxxx xxxxxxxxx pro xxxxxxxx xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx typ přípravku xx xxxxxxx xxxxxxxxx z těchto xxxxxx:
x) |
xxxxx xxxxxxxxx xxxxxxx xx xxx se xxxxxxxxx xx pokyny xxxx xxxxxxx doporučení vydané Xxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 26 xxxxxxxx 98/8/XX nebo xxxxxxx 81 xxxxxxxx (EU) x. 528/2012, xxxxx na xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxx xxxxxxx xxxxxx xx doporučení x xxxxxxxxxxx, xx xxxxxxx byl xxxxx z působnosti směrnice 98/8/XX nebo nařízení (XX) č. 528/2012, nebo xx byl příslušný xxx xxxxxxxxx jedním x xxxxxxxxx, xxx xxxxx xxxx účinná xxxxx xxxxxxxx, x xxxxx xxxx xxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxxxx přijatém podle xx. 3 odst. 3 xxxxxxxx (EU) x. 528/2012 xxxx v nových, xxxxxxxxx xxxxxxxx xxxxxxxxxxxx Xxxxxx; |
x) |
xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx a krmiva xxxxxxxxx x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
x) |
xxxxxxxx xxxxxxxxx xxxxx xxxxx nařízení (XX) x. 528/2012 k xxxxxxxxx xxxx přípravku, xxx xxxx xxxx xxxxx směrnice 98/8/ES, v důsledku xxxxx působnosti těchto xxxx přípravků a obsahuje xxxxx zařazenou xx xxxxxxxx xxxxxxxx pro původní xxx xxxxxxxxx, xxx xxxxxx xxx xxxx. |
Xxxxxx 16
Xxxxxxxxxx o xxxxx xx xxxxxxxx
1. Xxxxxxxxxx x xxxxx oznámit xxxxx, xxxxx xx xxxxxxxxx xxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxx xxxxxx 15, předkládá xxxxxxxxxxxxxxx xxxxxxxxx kterákoli xxxxx, xxx xx zájem xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxxxxxx x xxxxxxxxxxxxx příjemců:
a) |
Komisi xxxxxxxxxx dvanáct měsíců xx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx uvedených x xx. 15 xxxx. x); |
x) |
xxxxxxxx xxxxxxxxxx 30. xxxxx 2015 x xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x); |
x) |
Xxxxxx xxxxxxxxxx 30. října 2015 v xxxxxxxxx xxxxxxxxx x čl. 15 xxxx. x). |
2. Xxxxxxxxxx musí xxxxxxxxx xxxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) musí xxxxxxxxxx xxxxxxxxx opodstatněné xxxxxxxxxx, x xxxx vyplývá, xx xxxx xxxxxxx xxxxxxx xxxxxxxx x xxx xxxxxxx.
3. Xxxxx bylo xxxxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 xxxx. x) xxxx x) x Xxxxxx xxxxxxx xx xxxxxxxxxx x xxxxxxxxx xxxxx x závěru, xx xxxxxxxx 6 není xxxxxxxxxx, x xxxxxxxx, xx xxxx splněny xxxxxxxx xxx xxxxxxxx uvedené x xx. 15 xxxx. x), xxxxxxx x tom xxxxxxxx.
4. Xxxxx xxxx xxxxxxxxxx xxxxxxx v případě uvedeném x xx. 15 xxxx. x) xxxx pokud Xxxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 3, xxxxxxxx agentura xxxx informaci elektronickými xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. Xxx xxxxx xxxxxx nařízení xx xxxxxxxxxx xxxxx xx. 3x xxxx. 3 xxxxxxx pododstavce xxxxxxxx (XX) x. 1451/2007 xxxxxxxx xx xxxxxxxxxx xxxxx xxxxxx xxxxxxxx.
5. Xxxxxxxxx xxxxx, která má xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxx xxxx xxxxxx xxxxx xxxxxx 17 xx xxxxx xxxxxx xxx xxx zveřejnění xxxxx odstavce 4.
6. X xxxxxxxxx xxxxxxxxx x čl. 15 písm. x) x x) xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx považuje za xxxxxxxxx xxxxxxxxxx x xxxx xxxxxxxxx k dalšímu xxxxxxxx, xxxxx jsou xxxxxxx tyto xxxxxxxx:
x) |
xxxxxxxxx xxxxxx látka xx xxx zařazena xx xxxxxxxx xxxxxxxx; |
x) |
xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx státu xxx xxxxxxxxxx účinnou xxxxx xxx obsahuje xxxxxxx xxxxx, xxxxx xxxx xxxxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx; |
x) |
účastník, který xxxxxxxxx xxxxxxxx dokumentaci, xxxxx, xx xx xxxxx o xxxxxxx xxxx kombinace látky x xxxx xxxxxxxxx. |
Xxxxxx 17
Xxxxxx oznámení
1. Oznámení xxxxx xx. 14 xxxx. 2 x 3 xxxx xx. 16 odst. 5 xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxxxxx xxxx být xxxxxxxxxx ve xxxxxxx XXXXXX. Xxxx obsahovat xxxxx xxxxxxx x xxxxxxx X.
3. Xxxxx není x xxxxxxx XX pro xxxxxxxx xxxxxxx látku xxxxxx xxxxxxxxx příslušný xxxxx, xxxxxxxxx xxxxxxxxxxx agenturu x xxxxx jím xxxxxxxxx xxxxxxxxxxx xxxxxx, xxxxx xx xxxxxxxx x xxxxxxx x xxxxxxx 81 xxxxxxxx (EU) x. 528/2012, x xxxxxxxx písemné xxxxxxxxx xxxxxxxxxxx, xx xxxxxxxxx xxxxx xxxxxxxx s xxx, že dokumentaci xxxxxxx.
4. Xx xxxxxxxx xxxxxxxx x xxx xxxxxxx xxxxxxxx Xxxxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxx xxxxxxxxx podle nařízení (XX) č. 564/2013. Xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xx 30 dnů xx přijetí uvedené xxxxxxxxx, xxxxxxxx xxxxxxxx xxxxxxx x uvědomí x xxx xxxxxxxxxxxx x Xxxxxx.
5. Xx xxxxxxxx xxxxxxxx xxxxxxxx xx 30 xxx xxxxx, xxx oznámení xxxxxxxx xxxxxxxxxx uvedeným v xxxxxxxx 2. Pokud xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxx, poskytne xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxx 30 dnů, xxx své xxxxxxxx xxxxxxx xxxx opravil. Xx xxxxxxxx xxxx 30xxxxx xxxxx xxxxxxxx xx 30 dnů xxx xxxxxxxx, že xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx 2, nebo xxxxxxxx xxxxxxx, x xxx rozhodnutí sdělí xxxxxxxxxxxx x Xxxxxx.
6. V xxxxxxx x xxxxxxx 77 xxxxxxxx (XX) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 4 xxxx 5 podat xxxxxxx xxxxxxxxxx.
7. Xxxxx xxxxxxxx vyhovuje xxxxxxxxxx xxxxx odstavce 5:
x) |
v xxxxxxx, že xxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 14 odst. 2 xxxx 3, agentura neprodleně xxxxxxxxxxx xxxxxxxxx v xxxxxxxxx xxxxxxxx se xxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx; |
x) |
x xxxxxxx, xx xxxxxxxx bylo xxxxxxxxxx xxxxx čl. 16 xxxx. 5, xxxxxxxx neprodleně xxxxxxxxx Komisi, že xxxxxxxxxx bylo vyhověno. |
Xxxxxx 18
Xxxxxxxx xx xxxxxxxx xxxxxxxx
Xxxxx xx xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxx za xxxxxxxxx v souladu x xx. 16 xxxx. 6 nebo xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxxx požadavků x xxxxxxx x xx. 17 xxxx. 7 písm. b), zařadí Xxxxxx kombinaci látky x xxxx xxxxxxxxx xx xxxxxxxx přezkumu.
Xxxxxx 19
Informace x xxxxxxx, xxxxx xxxxxx xxxxxx xxxxxxxxxxx v xxxxx programu přezkumu
Xxxxx xxxxxx xx xxxxx xxxxxxxxx x xx. 16 xxxx. 5 obdrženo xxxxx xxxxxxxx nebo xxxxx xxxx xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx agenturou podle xx. 17 xxxx. 4 xxxx 5, xxxxxxxx o tom xxxxxxxxx členské xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxx 20
Xxxxxxxxxx Xxxxxx x látkách, které xxxxxx nadále xxxxxxxxxxx x xxxxx programu xxxxxxxx
Xxxxxx připraví xxxxx xxxxxxxxxx o neschválení xxxxx čl. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) č. 528/2012 x xxxxxx xxxxxxxxx:
x) |
xxxxx xxxxxxxx informuje Xxxxxx x xxxxxxx odstoupení xxxxxxxxx xxxxx xx. 12 xxxx. 3 xxxxxx xxxxxxxx; |
b) |
pokud xxxxx xxxxx xxxxxxxx xxxxxxxx ve lhůtách xxxxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx xxxx xxxxx xxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxx xx. 17 odst. 4 xxxx 5; |
x) |
xxxxx xxxx xxxxxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 tohoto xxxxxxxx a byly xxxxxxxx xxxxxxxxx podle xx. 17 xxxx. 5 xxxxxx xxxxxxxx, xxx xxxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx. |
V případě xxxxxxxx x xxxxxx pododstavci xxxx. x) xx xxxxx xxxxxxxxxx o xxxxxxxxxxx xxxxxxxx xx xxxxxx látku, na kterou xx xxxxxxxx xxxxxxxxx xxxxxxxx v příloze II xxxxxx xxxxxxxx, avšak xxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx x xxxxxxxxx.
XXXXXXXX 4
XXXXXXXXX XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx pro xxxxx xxxxxxx x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx pokračovat x&xxxx;xxxxxxxxxxx svého stávajícího xxxxxxx xxxx xxxxx xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, který xxxxxxx ze xxxxxxxxx xxxxxx xxxxx xxxxxxx x čl. 15 xxxx. x) x x), tuto xxxxx xxxxxxxx xxxx z xx xxxxxx. V xxxxxx případech:
a) |
nesmí xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xxxx xxxxxx xxxxxx xxxxxxxx v platnost; |
b) |
stávající xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;30 xxxxxx xx xxx xxxxxx xxxxxx xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx stávajícího systému xxxx xxxxx xxxxxxxx xx&xxxx;xxx a používání xxxxxxxxxx xxxxxxxxx, který xxxxxxx xx stávající účinné xxxxx xxxxxxx v xx. 15 xxxx. x), xxxx xxxxx xxxxxxxx xxxx x xx vzniká. V xxxxxx xxxxxxxxx:
x) |
xxxxx být xxxxxxxx xxxxxxxxx nadále xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;24 xxxxxx xx xx x xxxx xxxxxxxxx událostí, xxxxx xxxxxxx xxxxxxx:
|
x) |
xxxxxxxxx xxxxxx biocidního xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;30 xxxxxx xx té z xxxx xxxxxxxxx událostí, xxxxx xxxxxxx xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx může xxxxxxxxxx v uplatňování xxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxx dodávání xx&xxxx;xxx x&xxxx;xxxxxxxxx biocidního xxxxxxxxx, xxxxx xxxxxxx ze xxxxxxxxx xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 xxxx. 4 xxx xxxxxxxxx xxx xxxxxxx, xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. X xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx na trh x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx, kdy xxxxxxxx provedla elektronické xxxxxxxxxx xxxxx xxxxxx 19 x |
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx přípravku xxxxx xxx dále využívány xx&xxxx;xxxxxxxx xxxxxx po xxxx xxxxxxxxx zveřejnění. |
Xxxxxx 22
Xxxxxxxx použití
1. Aniž xx dotčen xx. 55 xxxx. 1 xxxxxxxx (XX) x. 528/2012, xx xxxxxxxx xxxxxx xx xxxx xxxxxxxxxx x xxxxxxxxxxx xxxxxxxxx účinné xxxxx, xxxxx xxxxxxx xxxx xxxxxxxx xxxx xxxxxxxxx xxxxxxx látku xx xxxxxxxxx x xxxxxx xxxxxxxxx x xx. 5 xxxx. 2 prvním xxxxxxxxxxx xxxx. x) xxxx x) nařízení (XX) x. 528/2012, xxxxx členský xxxx xxxx xxxxxxxxx Xxxxxx xxxxxxxxxxx xxxxxx x xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx členský stát xxxxxxxx xxxxxxxxxxx žádost xxxxxxxx prostřednictvím xxxxxxxxx. Xxxxx xxxxxx obsahuje xxxxxxx xxxxxxxxx, žádající xxxxxxx xxxx xxxx xxxxxxx předložit nedůvěrné xxxxx.
3. Xxxxxxxx zveřejní žádost xxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx. Xxxxxxx státy xxxx xxxx osoby xxxxx xxxxx xxxxxxxxxx xx xxxxx 60 xxx xx xxxxxxxxxx.
4. Xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxx Xxxxxx xxxxxxx xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 528/2012, xxxxx umožní xxxxxx xxxxxxxx xxxxxxxxx, xxx xxxxxxxxx x xxxx xxxxx, obsahují ji xxxx x xx xxxxxxxx, xx xxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx xx x xxxxx xxxxxxxx xxxxx x xxxxxxx x xxxxxxxxxxxxxx právními předpisy x x xxxxxxxx podmínek odstavce 5 x xxxxxxxxx dalších xxxxxxxx xxxxxxxxx Xxxxxx.
5. Xxxxxxx xxxx, xxxxx xx xxxxxxxx xxxxxxxx:
a) |
xxxxxxx, xx xxxxx xxxxxxxxx bude omezeno xx xxxxxx případy x xxxxxxx xxxx, xxx xxxx xxxxxx podmínky xxxxxxxx 1; |
x) |
xxxxxx vhodná opatření xx xxxxxxxx xxxxx, aby xxxxxxxx minimalizaci xxxxxxxx xxxxxxx, zvířat xxxx xxxxxxxxx prostředí; |
x) |
xxxxxxx, aby xx hledala alternativní xxxxxx xxxx aby xxxx xxxx xxxx xxxxxxxxx xxxxxxxxx odchylky xxxxxxxxxx žádost x xxxxxxxxx xxxxxx xxxxx x xxxxxxx xxxxxxx 7 xxxxxxxx (XX) č. 528/2012. |
KAPITOLA 5
XXXXXXXXX XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx xx xxxxxxxx (XX) x. 1451/2007.
Xxxxxx xx xxxxxxx nařízení xx považují za xxxxxx xx xxxx xxxxxxxx.
Xxxxxx 24
Xxxxx v xxxxxxxx
Xxxx nařízení xxxxxxxx x xxxxxxxx dvacátým xxxx xx xxxxxxxxx x Úředním xxxxxxxx Xxxxxxxx xxxx.
Xxxx xxxxxxxx xx xxxxxxx x celém xxxxxxx a xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx státech.
X Xxxxxxx xxx 4. srpna 2014.
Xx Xxxxxx
xxxxxxxx
Xxxx Xxxxxx XXXXXXX
(1)&xxxx;&xxxx;Xx. xxxx. L 167, 27.6.2012, x. 1.
(2) Nařízení Xxxxxx (XX) x. 1451/2007 xx xxx 4. prosince 2007 o xxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx uvedeného x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady 98/8/XX x xxxxxxx xxxxxxxxxx přípravků xx xxx (Xx. xxxx. X 325, 11.12.2007, x. 3).
(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX xx xxx 16. xxxxx 1998 x xxxxxxx biocidních xxxxxxxxx xx trh (Xx. xxxx. X 123, 24.4.1998, x. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxx xxxxx (xxxxxxx senátu) xx xxx 1. xxxxxx 2012 (xxxxxx x xxxxxxxxxx o xxxxxxxxx xxxxxx: Xxxxxxxxxxx Xxxxxxx – Xxxxxxx) – Xöxx XxxX xxxxx Xxxxx XxxX (xxxxxxx xxxxxxxxxx přípravků xx xxx – xxxxxxxx 98/8/XX – čl. 2 odst. 1 xxxx. x) – xxxxx „biocidní xxxxxxxxx“ – přípravek, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx je xxxx, odpuzuje xxxx xxxxxxxxxxx), X-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx nařízení Xxxxxx (XX) č. 88/2014 xx xxx 31. ledna 2014, xxxxxx xx xxxxxxx xxxxxx xxx změnu xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (EU) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx trh x&xxxx;xxxxxx xxxxxxxxx (Xx. xxxx. L 32, 1.2.2014, x. 3).
(6) Nařízení Evropského xxxxxxxxxx x Xxxx (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx a balení xxxxx x xxxxx, x xxxxx a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/ES a x xxxxx nařízení (XX) x. 1907/2006 (Xx. věst. X&xxxx;353, 31.12.2008, x. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx nařízení Komise (XX) x.&xxxx;564/2013 xx xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx xxxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) č. 528/2012 x&xxxx;xxxxxxxx biocidních xxxxxxxxx xx xxx a jejich xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, s. 17).
(8) Nařízení Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1907/2006 xx xxx 18. xxxxxxxx 2006 x registraci, xxxxxxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx xxxxxxxx 1999/45/ES a x xxxxxxx xxxxxxxx Xxxx (EHS) x.&xxxx;793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX a xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX I
Xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx podle xxxxxx 17
Xxxxxxxx podle xxxxxx 17 xxxxxxxx xxxx xxxxxxxxx:
1) |
xxxxx, že látka xx xxxxxxxxx účinnou xxxxxx xx xxxxxx xx. 3 xxxx. 1 xxxx. x) nařízení (XX) x. 528/2012; |
2) |
xxxxx x xxxx/xxxxxx přípravku, xx xxxxx/x xx xxxxxxxx xxxxxxxx; |
3) |
xxxxxxxxx x xxxxx xxxxxxxx, xxxxx xxxx xxxxxx xxx xxxxx xxxxxxx x xxxxxxxxx či xxxxxxxx xx xxxxxxx X xxxxxxxx (XX) x. 528/2012, xxxxx x xxxxxxxxx xxxxx xxxxxx xxxxxxxxx; |
4) |
xxxxxxxxx xxxxxxx v oddílech
|
5) |
xxxxx xxxx xxxx xxxxxxxx xxxxxxx v případě xxxxxxxx x xx. 15 písm. x), xxxxx, že látka byla xx xxxx xxxx xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxx v den xxxxxxxx xxxx zveřejnění xxxxxxxxxx xxxx pokynů xxxxxxxxx xx xxxxxxxx xxxxxxx. |
XXXXXXX II
XXXXXXXXX XXXXX X XXXX XXXXXXXXX ZAŘAZENÉ XX XXXXXXXX XXXXXXXX XXX 4. SRPNA 2014
XXXX 1
Xxxxxxxxx xxxxxx xxxxx x xxxx přípravku xxxxxxxxxxx xx dni 4. xxxxx 2014, s výjimkou xxxxxxxxxx jiných xxxxxxxxxxxxx xxx těch, xxxxx xxxx xxxxxxxx uvedeny x xxxxxxxxx 1017 x 1019.
Xxxxx xxxxxxx |
Xxxxx látky |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx XX |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1 |
xxxxxxxxxxx |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
6 |
5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx xxxxxxxx |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
DE |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx salicylová |
XX |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
xxxxxx-1-xx |
XX |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
xxxxxxxx xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx xxxxxxxx/2-xxxxxxxxxxxxxxx xxxxxxxx |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
DE |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-xxxxxxxxxxx-8,9-xxxxxxxxx-1,2,6,6x,12,12x-xxxxxxxxxxxxxxxxx[3,4-x]xxxx[2,3-x]xxxxxxx-6-xx (rotenon) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
85 |
xxxxxxxxx |
XX |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
92 |
xxxxxxx-2-xx |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (glutaraldehyd) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
154 |
chlorofen |
X |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-fenoxyethan-1-ol |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
XX |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx xxxxxxxx |
XX |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
180 |
(natrium-kakodylát) – natrium-dimethylarsinát |
XX |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
185 |
tosylchloramid, sodná xxx (xxxxx xxx xxxxxxxxxxxxxxx – xxxxxxxxx X) – (X-xxxxx-4-xxxxxxxxxxxx-1-xxxxxxxxxx |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
xxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
188 |
xxxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
195 |
natrium-bifenyl-2-olát |
ES |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
198 |
N-[(trichlormethyl)sulfanyl]ftalimid (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
235 |
xxxxxx |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
DE |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
253 |
xxxxxxxxxx-3,5-xxxxxxxx-1,3,5-xxxxxxxxxx-2-xxxxx (xxxxxxx) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
279 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X′,X′-xxxxxxxx-X-(4-xxxxxxxxxxx)xxxxxxxxxx (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (dichlofluanid) |
XX |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
289 |
xxxxxxxxxxxx xxxxx |
XX |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
292 |
[(1,3-xxxxx-1,3,4,5,6,7-xxxxxxxxx-2X-xxxxxxxx-2-xx)xxxxxx]-xxxxx-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx xxxxx/xxxxxx xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx xxxxxxxx/xxxxx/xxxxxx xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx xxxxx |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
315 |
butan-2-on-peroxid |
HU |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
xxxxxxxxxxx |
UK |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
X-(3-xxxxxxxxxxx)-X-xxxxxxxxxxxxx-1,3-xxxxxx (diamin) |
XX |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
336 |
N,N′-dimethyl-2,2′-disulfandiyldibenzamid (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (BIT) |
ES |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
346 |
natrium-dichlorisokyanurát xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (MES) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
xxxxxxxxx |
DK |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx x xxxxxxxxxxxxxxxx (XXXxxx)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
365 |
pyridin-2-thiol-1-oxid, xxxxx xxx (pyrithion xxxxx) |
SE |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (HHT) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
382 |
1,3,4,6-tetrakis(hydroxymethyl)hexahydroimidazo[4,5-d]imidazol-2,5-dion (XXXX) |
XX |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
387 |
dimorfolinomethan (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
PL |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
397 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
401 |
xxxxxxx |
SE |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
403 |
xxx |
XX |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
405 |
oxid xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
NL |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
432 |
xxxxxxxx sodný |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
DE |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
439 |
peroxid xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
PL |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
450 |
xxxxxxxx xxxxxxxx |
XX |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
xxxxxxxxxxxxx xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
IT |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
458 |
xxxxx amonný |
UK |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
473 |
xxxxxxxxxx x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
491 |
xxxx chloričitý |
PT |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
494 |
2,2-xxxxxx-2-xxxxxxxxxxxx (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
515 |
xxxxxx amonný |
XX |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
522 |
xxxx-1-xxx-1λ5-xxxxxxx-2-xxxxxxx |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
529 |
brommonochlorid |
NL |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
531 |
(xxxxxxxxx)xxxxxxxx |
UK |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx komplex (xxxxxxxxx xxxx) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (CHDG) |
XX |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
XX |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
559 |
[(benzothiazol-2-yl)sulfanyl]methyl-thiokyanát (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (prallethrin) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
563 |
kalium-(E,E)-hexa-2,4-dienoát (xxxxxx xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
XX |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
571 |
2-oktyltetrahydroisothiazol-3-on (OIT) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
577 |
xxxxxxxx(xxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
578 |
X2-xxxx-xxxxx-X4-xxxxxxxxxxx-6-(xxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX/xxxxxxxxxxxxxxxxxxxxxxxxxx) |
XX |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
590 |
3-(4-isopropylfenyl)-1,1-dimethylmočovina/isoproturon |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxx) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
X-[(6-xxxxx-2-xxxxxxxxxx[4,5-x]xxxxxxx-3(2X)-xx)xxxxxx]-X,X-xxxxxxxx-xxxxxxxxxxxxx (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (DBDCB) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
961 |
oxid xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx vápenato-hořečnatý/hydratované dolomitické xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (cyfenothrin) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
608 |
xxxxxxxx(xxxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
609 |
xxx- a xxxxx-x-xxxxxxx-3,8-xxxx (xxxx) (xxxxxxxxxx) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
619 |
3-jodprop-2-yn-1-yl-N-butylkarbamát (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
MT |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
XX |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxx (XXXXX/XXXX) |
IT |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
648 |
4,5-dichlor-2-oktylisothiazol-3(2H)-on (4,5-dichlor- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
656 |
xxx(5-xxxxxxxxxxxxxxxx-3-xx)xxxxxx (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
EL |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
666 |
[(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxx) |
XX |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
667 |
xxxxx(X12-18)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-18)) |
IT |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX/XXX (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (DDAC) (X8-10) |
XX |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
690 |
xxxxx(X12-X18)xxxxxx(xxxxxxxx)xxxxxxxx xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (ADBAS) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx xxxxxxxxxx (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
margosa, Xxxxxxxxxxx indica, výtažek |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
724 |
alkyl(C12-C14)dimethylbenzylammoniumchlorid (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
725 |
alkyl(C12-C14)ethylbenzylammoniumchlorid (ADEBAC (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
731 |
xxxxxxxxx stračkolistá, Chrysanthemum xxxxxxxxxxxxxxxx, výtažek |
ES |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
744 |
xxxxxxxxx zvrhlá, Xxxxxxxxx hybrida, xxxxxxx/xxxxxxxxxxx xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
XX |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
779 |
xxxxxxx produkty xxxxxxxxx kyseliny x X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (glukoprotamin) |
XX |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
792 |
komplex xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
SE |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (ikaridin) |
XX |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
797 |
1-((X)-3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxxxxxxxxx (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-methylprop-1-en-1-yl)cyklopropan- 1-xxxxxxxxxx (xxxx stereoisomerů) (imiprothrin) |
XX |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
790 |
5-chlor-2-(4-chlorfenoxy)fenol (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (chlothianidin) |
XX |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
952 |
Xxxxxxxx sphaericus 2362, kmen XXXX-1743 |
IT |
mikroorganismus |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. israelensis, xxxx XX3X |
IT |
xxxxxxxxxxxxxxx |
xxxx relevantní |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
957 |
Bacillus xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx relevantní |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Einecs 247-500-7) a 2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 220-239-6), xxxx (3:1) (xxxx XXXX/XXX) |
FR |
xxxx |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
939 |
xxxxxxx xxxxx (vyráběný xxxxxx xxxxxxxx chlorné x xxxxxxxxx sodného xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
xxxxxxxxxxxxxx kyselina |
XX |
není xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx xxxxxx |
SE |
není relevantní |
xxxx xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (d-fenothrin) |
XX |
xxxx relevantní |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
931 |
xxxxxxxxxxxxxxxxxxxxxxx, X-X12-14(xx xxxxx xxxxxx), xxxxxxxx reakce x xxxxxxxxxxxx kyselinou (Xxxxxxxx 20) |
XX |
xxxx relevantní |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx reakce 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx k dispozici |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx oxidu titaničitého x xxxxxxxx xxxxxxxxxx |
XX |
xxxx x xxxxxxxxx |
xxxx x xxxxxxxxx |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
777 |
reakční xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx x xxxxxxxxx |
xxxx k dispozici |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
810 |
xxxxxxxxxxxxxx xxxx s xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
824 |
xxxxxxxx-xxxxxxxxx zeolit |
SE |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx xxxxxx |
XX |
xxxx x xxxxxxxxx |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1017 |
xxxxxxx xxxxxxxxxxx xx xxxxx xxxxxxxxxx (jako xxxxxxxxxxxx xx xxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxx xx xxxxxxxxxx) |
XX |
není x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
1019 |
xxxx xxxxxxxxx (jako xxxxxxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx x xxxxxxxxx |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
831 |
křemelina |
FR |
xxxxxxxxx xx xxxxxxx xxxxxxx |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
854 |
(RS)-3-alyl-2-metyl-4-oxocyklopent-2-enyl-(1R,3R;1R,3S)-2,2-dimetyl-3-(2-metylprop-1-enyl)-cyklopropankarboxylát (xxxx 4 xxxxxxx 1X xxxxx, 1X: 1R xxxxx, 1S: 1X xxx, 1X: 1X xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (xxxxxxxxxx) |
XX |
přípravek na xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
848 |
N-[(6-chlor-3-pyridyl)methyl]-N′-kyan-N-methylethanimidamid (xxxxxxxxxxx) |
BE |
přípravek xx xxxxxxx xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
835 |
xxxxxxxxxxxx/(X)-(3-xxxxxxxxxxx)xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx rostlin |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
843 |
4-brom-2-(4-chlorfenyl)-1-(ethoxymethyl)-5-(trifluormethyl)pyrrol-3-karbonitril (chlorfenapyr) |
XX |
xxxxxxxxx xx ochranu rostlin |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
859 |
xxxxxxx X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) x (xxxxxxxxxxx)xxxxxxxx (XXXXXX 203-439-8)/xxxxxxxxx xxxxxxxxx chlorid xxxxxx (XX Polymer) |
XX |
polymer |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
863 |
poly(biguanid-1,5-diylhexan-1,6-diyl) (XXXX) |
XX |
xxxxxxx |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
XX |
polymer |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
869 |
α-[2-(didecylmethylamonio)ethyl]-ω-[hydroxypoly(oxyethylen)-propionát] (Xxxxxx 26) |
XX |
xxxxxxx |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx xxxxxx) |
EL |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
XXXX 2
Xxxxxxxxx účinné xxxxx x xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxx 4. xxxxx 2014
Xxxx část xxxx xxxxxxx obsahuje
— |
kombinace xxxxx x xxxx přípravku xxxxxxx x xxxxxxx níže, xxxxxx případných xxxxxxxxx, |
— |
xxxxxxxx xxxxxxxxx všech kombinací xxxxx x xxxx přípravku xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, xxxxx xxxx xxxxxxx v tabulce, x |
— |
xxxxxxxx xxxxxxxxx všech xxxxxxxxx xxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx 4. srpna 2014, x xxxxxxxx těch, xxxxx xxxx xxxxxxxx xxxxxxxxx. |
Xxxxxxxxx xxxxx x xxxx přípravku x xxxxxxxxxxxxx xxxxxxxx xx xxxx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxxx podle xxxxxx 20, xxxxxxxx xxxxx xxxxx nepodá xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxx xx. 14 xxxx. 3 nebo xxxxx xx takové xxxxxxxx xxxxxxxxx xxxxx xx. 17 odst. 4 xxxx 5.
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Členský xxxx xxxxxxxxx |
Číslo ES |
Číslo XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx xxxxxxxxxx xxxxx položky 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (xxx xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx položka 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx položka 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx xxxxxxx |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
449 |
síran xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
XX |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
554 |
4-[(dijodmethyl)sulfonyl]-1-methylbenzen |
UK |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (viz xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
benzyldimethyl(oktadec-9-en-1-yl)amonium-chlorid (xxx xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
637 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx kokosového xxxxx) (viz položka 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx oleje) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
dialkyl(dimethyl)amonium-chloridy (alkyl xxxxxxx xx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx položka 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
xxxxxxx(X6-X12)xxxxxxxxxxxxxxx-xxxxxxxx (xxx xxxxxxx 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
xxxxxxx(X8-X18)xxxxxxxxxxxxxx-xxxxxxxx (xxx položka 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx xxxxxxx jiný xxx z xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxxxxxxxx xxxxx a xxxx zpracovaný xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx položka 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx xxxxxxxxxx xxxxx xxxxxxx 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
778 |
1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-[(1X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxx-3-xx (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx xxxxxxx dimethyl-adipátu, xxxxxxxx-xxxxxxxxx x dimethyl-sukcinátu x xxxxxxxxx xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
xxxx |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(dialkyl)dimethylamonium-chloridy, -bromidy xxxx -xxxxxx-xxxxxxx) (alkyly (X6-X18) xxxxxxxx x xxxxxxxxxx, odvozené xx xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx x xxxxxxxx xxxxx) (DDAC) |
IT |
směs xxxxx uvedených x xxxxxxx XXXXXX |
není relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -methyl-sulfáty) (xxxxxx (X8-X18) xxxxxxxx x xxxxxxxxxx, odvozené xx mastných xxxxxxx xxxx, xxxxxxxxxx xxxxx x xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x seznamu XXXXXX |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx nebo -xxxxxxxxx) (xxxxxx (C8-C22) xxxxxxxx a nenasycené, xxxxxxxx od mastných xxxxxxx xxxx, kokosového xxxxx x xxxxxxxx oleje) (XXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx XXXXXX |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
xxxx relevantní |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
1001 |
xxxxx(X12-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx než látka xxxxxxxxx xxx xxxxxxx 671) |
XX |
xxxx xxxxxxxxxx |
není relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
1002 |
alkyl(C12-C18)benzyl(dimethyl)amonium-chloridy(jiné xxx xxxxx xxxxxxxxx xxx xxxxxxx 667) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- xxxxxxxx (xxxx než xxxxx xxxxxxxxx xxx položku 725) |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx xxxxxxx 724) |
XX |
xxxx xxxxxxxxxx |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1006 |
fosforečnanové xxxx obsahující xxxxxxx, xxxxx, hliník x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1009 |
xxxxxxx(X8-X10)xxxxxxxxxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx položku 673) |
XX |
není xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx od xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxxx než xxxxx xxxxxxxxx xxx xxxxxxx 635) |
XX |
xxxx relevantní |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1012 |
xxxxxxxxxxxxxxxxx xxxxx, xxxxxxxx x xxxxxxxxx komplex/stříbrno-zinečnatý xxxxxx |
XX |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx xxxxxxxxx) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
Xxxx přípravků |
Lhůty xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 3 xxxx. x) |
Xxxxx pro xxxxxxxx xxxxxxxx xxxxxxxxxx podle xx. 7 xxxx. 2 písm. b) |
8, 14, 16, 18, 19 a 21 |
31.12.2015 |
31.3.2016 |
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
1 a 2 |
31.12.2018 |
31.3.2019 |
6 x 13 |
31.12.2019 |
31.3.2020 |
7, 9 x 10 |
31.12.2020 |
31.3.2021 |
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |